Objective: Allergic bronchopulmonary aspergillosis (ABPA) is a complicating factor of cystic fibrosis which can result in a devastating combination as lung disease progresses. The overlap between the signs and symptoms of the two conditions makes diagnosis problematic, even if standardized criteria are used. The objective of this study was to identify, in a group of cystic fibrosis patients, cases of ABPA by assaying IgE specific to recombinant Aspergillus fumigatus antigens and to compare the method with the Cystic Fibrosis Foundation diagnostic criteria.
Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a lung hypersensitivity disease mediated by an allergic late-phase inflammatory response to certain antigens of Aspergillus fumigatus. 1 In patients with cystic fibrosis (CF), the presence of atopic disease, bronchial hypersecretion and a certain difficulty in removing microorganisms from the respiratory tree can be listed as factors that facilitate colonization and possible sensitization to A. fumigatus. 2 There is bronchial colonization by A. fumigatus in 12 to 57% of CF patients, 3 and sensitization to the fungus may vary from 30 to 51% in all cases. 4 The prevalence of ABPA varies greatly, from 1 to 15%, 5, 6 and increases in line with patient age. 7 The duration of endobronchial colonization by Pseudomonas aeruginosa and colonization by Stenotrophomonas maltophilia represent risk factors for sensitization to Aspergillus and ABPA, respectively. 8 Allergic bronchopulmonary aspergillosis is a complicating factor of cystic fibrosis which can result in a devastating combination as lung disease progresses, 9, 10 and early diagnosis is of fundamental importance to preventing pulmonary damage and functional deterioration. 11 Despite recent advances in the understanding of ABPA immunopathology, diagnosis in patients with CF is still imprecise. 12 Even with the adaptation of the classic ABPA diagnostic criteria 13 for use with CF patients, 4,14 doubt very often remains when differentiating patients with ABPA from those who are only sensitized to the fungus.
The development of recombinant components of A. fumigatus antigens has made it possible to identify IgE specific to some of these allergens. It has been demonstrated that patients with ABPA react to a larger number of the recombinant allergens in this panel, some of which r Asp f2, f4 and f6 are considered specific to ABPA patients. [15] [16] [17] [18] This technique therefore appeared to be very promising for ABPA diagnosis.
The objective of this study was to identify cases of ABPA in a sample of CF patients, employing the technique of detecting IgE specific to the recombinant A. fumigatus allergens r Asp f2, f4 and f6 and to compare the results from this method with diagnoses based on the Cystic Fibrosis Foundation (CFF) standardized criteria. 14 
Methods
This was a cross-sectional study carried out during the routine clinical assessments of patients with diagnoses of CF, made in accordance with the CFF consensus statement criteria. 19 These patients were being treated at the Pediatric Pulmonology Section, Child Institute, at (Pharmacia-Diagnostics) machine. ImmunoCAPs were produced and employed for the titration of allergen specific serum IgE in accordance with specifications described by Crameri et al. 23 The results were converted into standardized RAST classes from 0 to 4, in accordance with the manufacturers instructions ( 
Results
Fifty-four CF patients were assessed during the study period and, of these, 39 were considered eligible, although just 32 agreed to participate and to attend for sample collection and testing. The mean age of the study group was 9.8 years (±3.8) and mean Shwachman score was 65 (±15) ( Table 2) . Eleven patients were identified as sensitized to A. fumigatus (34%). Just three of them had recombinant antigen specific IgE profiles that were compatible with ABPA. Three patients were identified as having ABPA according to the CFF criteria. 14 Two of them had IgE specific to the f2 and f4 fractions and therefore compatible with ABPA.
The other patient exhibited only sensitization with IgE specific to the f1 fraction (Table 3 ).
All patients had CT abnormalities suggestive of bronchiectasis. This examination does not, therefore, differentiate patients by presence or absence of ABPA.
Discussion
In this population of 32 children and adolescents with CF, two patients with ABPA and 11 individuals sensitized to the fungus were identified by means of skin tests, A. fumigatus specific IgE assay (RAST) and by testing for IgE specific to the recombinant allergens Asp f1, f2, f3, f4 and f6.
It was the difficulty of diagnosing ABPA in CF patients that motivated this study, which was the first opportunity there are no national data on these prevalence rates.
Estimates and descriptions of the prevalence of ABPA and of sensitization to A. fumigatus based only on classic criteria, even in developed countries, may be underestimated, since the difficulties in diagnosing ABPA in CF are universal. 10 Cunningham et al. 12 surveyed the criteria used to diagnose ABPA in specialist clinics in the United Kingdom. Tests such as precipitins, specific IgE and skin tests for A. fumigatus, eosinophil count in peripheral blood, total IgE and chest radiography were performed routinely and, on average, the centers performed four of the six tests annually. Nevertheless, there was a large variation in the criteria used to confirm diagnosis in order to start treatment. Prevalence data therefore depends on which criteria and laboratory tests are considered when defining sensitization and ABPA. 14 It is also known that immunological test results can fluctuate over time, with intra-individual variation. 25 Additionally, there are reports of patients who had presented sensitization and then ceased to have test results compatible with sensitization during follow-up. 26 In this sample, the association of positive skin test for A. fumigatus hypersensitivity, absolute number of eosinophils in peripheral blood over 500/mm 3 , serum IgE assay result over 500 UI/ml and positive RAST for A.
fumigatus, offered good specificity for ABPA diagnosis. In addition to the importance of these tests for periodic screening of patients at risk from ABPA, the combination is useful because these tests are simpler and more likely to be available than the test for A. fumigatus recombinant antigen specific IgE.
In patients with CF, the relationship between high serum IgE and ABPA has already been reported by several authors, and this is one of the laboratory variables included in the classic diagnostic criteria. 5, 27 What is peculiar to CF patients is that these IgE levels may not be so high, 28, 29 as the CFF consensus emphasizes in suggesting that annual ABPA screening be performed if there is a strong clinical suspicion even when IgE < 500 UI/ml. 14 The level of serum IgE varies according to the phase of disease activity, 1 and reduced levels after treatment with corticosteroids is another factor to be taken into account when diagnosing ABPA. 4, 5 Banerjee et al. 17 protein. 30 The r Asp f6 antigen has been identified as a protein specific to the hyphae of Aspergillus, and these hyphae are only present in ABPA. 31 Therefore, identification of IgE specific to the r Asp f4 and r Asp f6 antigens can also be used as a marker specific to ABPA. 30 In our sample, and r Asp f6, and an association with total serum IgE over 1,000 UI/ml allowed ABPA to be confirmed with high specificity (100%) and sensitivity (64%). Under this treatment, specific and total IgE levels were reduced but did not normalize, and pulmonary function remained stable despite the treatment. Testing for IgE to recombinant antigens of A. fumigatus was considered useful for identifying patients at increased risk of ABPA, but laboratory data was not sufficient to monitor treatment.
Allergic bronchopulmonary aspergillosis is an infrequent complication of CF and diagnostic confirmation remains a challenge. Despite the efforts directed at establishing diagnostic criteria adapted to CF patients, diagnostic failures still occur. We performed a systematic investigation comparing two distinct strategies, the CFF criteria and the detection of IgE specific to recombinant antigens, and found that the diagnostic conclusions were discordant.
Assaying IgE to recombinant antigens of A. fumigatus appears to us to be a promising technique for the early detection of sensitization to the fungus and of ABPA itself, perhaps during a phase with little clinical pulmonary symptomology. However, the true utility of this laboratory method to the clinical practice has not yet been defined.
Despite the high specificity previously described for this laboratory method, neither diagnostic confirmation nor the treatment can be divorced from the clinical condition of the patients. Further longitudinal studies with larger numbers of patients remain necessary to achieve diagnosis during the diverse stages of the disease and for detecting relapses and establishing cure criteria after therapeutic intervention.
